Maya R. Chilbert

Maya R. Chilbert

Auto-generated profile, based on publicly available information

Maya R. Chilbert

University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MCMaya R Chilbert
Maya R Chilbert
DVDylan VanDuyn
Dylan VanDuyn
SSSara Salah
Sara Salah
CCCollin Clark
Collin Clark
QMQing Ma
Qing Ma
Cardiovascular disease is one of the leading causes of death around the world with various efforts being made to reduce risk in patients through preventive measures. One major method for prevention has been managing cholesterol, particularly low-density lipoprotein to decrease atherosclerotic plaque burden, potentially decreasing future cardiac complications. Statins have been the gold standard therapy for hypercholesterolemia treatment due to their ease of dosing, limited drug interactions, and favorable safety profile. Unfortunately, statin therapy alone is not always effective enough to adequately control a patient’s elevated lipid levels and combination therapy may be warranted. Ezetimibe is commonly added to regimens to help augment cholesterol lowering by inhibiting the absorption of cholesterol. The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial option for cholesterol management in addition to the only available combination of moderate intensity simvastatin and ezetimibe. We aimed to identify potential beneficial effects of ezetimibe by comparing its use in combination with high-intensity rosuvastatin compared to a statin therapy alone or in combination with moderate intensity simvastatin through a literature review. The current evidence indicated that combination therapy outperformed statin monotherapy in reduction of low-density lipoprotein cholesterol and patients were more likely to achieve their target low-density lipoprotein cholesterol goal level. This suggests rosuvastatin/ezetimibe combination holds a potential place in therapy for patients requiring a more aggressive reduction in cholesterol to help prevent atherosclerotic disease.

25 February 2024 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
MCMaya R. Chilbert
Maya R. Chilbert
KZKimberly Zammit
Kimberly Zammit
UAUzma Ahmed
Uzma Ahmed
ADAmanda Devlin
Amanda Devlin
SRSara Radparvar
Sara Radparvar
AWAshley E. Woodruff
Ashley E. Woodruff

5 April 2020 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
EBEric G. Boyce
Eric G. Boyce
CHChristy S. Harris
Christy S. Harris
ABAngela L. Bingham
Angela L. Bingham
ECEmily Chan
Emily Chan
SCScott A. Chapman
Scott A. Chapman
NYNancy S. Yunker
Nancy S. Yunker

1 August 2021 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
PMPatrick McGrath
Patrick McGrath
BKBrian Kersten
Brian Kersten
MCMaya R. Chilbert
Maya R. Chilbert
CRCaroline Rusch
Caroline Rusch
MNMegan Nadler
Megan Nadler

5 January 2024 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
MCMaya R. Chilbert
Maya R. Chilbert
NANicole Albanese
Nicole Albanese
NCNicole Cieri-Hutcherson
Nicole Cieri-Hutcherson
RORichard O’bRocta
Richard O’bRocta
AWAshley E. Woodruff
Ashley E. Woodruff
JMJaime Maerten-Rivera
Jaime Maerten-Rivera

1 July 2022 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
ODOlivia Bs Denny
Olivia Bs Denny
AWAshley E. PharmD Woodruff
Ashley E. PharmD Woodruff
KMKevin PharmD Mills
Kevin PharmD Mills
MCMaya R. PharmD Chilbert
Maya R. PharmD Chilbert
Tirofiban has been used historically as a bridge to platelet inhibition with clopidogrel in ST-segment myocardial infarction (STEMI) during percutaneous coronary intervention (PCI) to prevent stent thrombosis. However, ticagrelor and prasugrel reach similar levels of platelet inhibition at 30 minutes to that of clopidogrel at 6 hours, challenging the need for long-duration tirofiban. This 1-year, retrospective cohort study compared ischemic and bleeding outcomes of short-duration versus long-duration tirofiban regimens in patients with STEMI who received ticagrelor or prasugrel at the time of PCI. The primary outcome was major adverse cardiovascular events (MACEs) including cardiovascular mortality, recurrent myocardial infarction, urgent target vessel revascularization, or stroke. Secondary outcomes included individual MACE, all-cause mortality, bleeding events defined by the International Society on Thrombosis and Hemostasis, thirty-day readmissions for MACE and bleeding, and tirofiban pharmacy cost. A total of 283 charts were reviewed and 177 included (short duration n = 57; long duration n = 120). MACE rates were similar between short-duration and long-duration groups (0 [0%] vs. 5 [4.2%]; P = 0.18), including 4 cardiovascular deaths and 1 recurrent myocardial infarction. Bleeding event rates were also similar in short-duration versus long-duration groups including major bleeds (2 [3.5%] vs. 2 [1.7%]; P = 0.60) and clinically relevant nonmajor bleeds (3 [5.3%] vs. 9 [7.5%]; P = 0.75). Cost analysis indicated lower pharmacy cost with the short-duration group. In this cohort of patients with STEMI receiving a fast-acting P2Y12 inhibitor, the length of tirofiban infusion did not affect ischemic or bleeding outcomes, yet short-duration regimens were lower cost.